{"contentid": 487961, "importid": NaN, "name": "FibroGen and AstraZeneca\u00e2\u0080\u0099s roxadustat to face FDA AdCom", "introduction": "USA-based FibroGen and its partner, AstraZeneca, have revealed that the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration will hold an advisory committee (AdCom) meeting to review the new drug application for roxadustat in the USA", "content": "<p>USA-based FibroGen (Nasdaq: FGEN) and its partner, AstraZeneca (LSE: AZN), have revealed that the Cardiovascular and Renal Drugs Advisory Committee of the US Food and Drug Administration will hold an advisory committee (AdCom) meeting to review the new drug application for roxadustat in the USA. The companies have not received a confirmed AdCom meeting date from the FDA.</p>\n<p>&ldquo;While disappointed with the news today, FibroGen and AstraZeneca are committed to working with the FDA to bring roxadustat to patients with anemia of CKD in the US as soon as possible,&rdquo; said Enrique Conterno, chief executive of FibroGen. &ldquo;We continue to be confident in the efficacy and safety profile of this potential new medicine based on positive results from a global Phase III program encompassing more than 8,000 patients.&rdquo;</p>\n<p>Roxadustat has been approved in China, Japan and Chile for the treatment of anemia of CKD in both non-dialysis dependent (NDD) and dialysis-dependent (DD) adult patients.</p>\n<h2><strong>ICER previously said data not adequate</strong></h2>\n<p>Commenting on the situation, the USA&rsquo;s Institute for Clinical and Economic Review (ICER) noted today that, at its February 11 meeting, its independent appraisal committee voted unanimously (15-0) that the evidence is not adequate to demonstrate that roxadustat -- an investigational treatment for anemia associated with chronic kidney disease -- provides a net health benefit over currently available alternatives.</p>\n<p>Less than three weeks later, Fibrogen revealed that the FDA made a late-breaking decision to convene a public AdCom meeting to dig deeper into the drug&rsquo;s safety and efficacy data.</p>\n<p>This decision will almost certainly postpone the drug&rsquo;s March 20 PDUFA date, the ICER opined, pointing out that media outlets also noted that there&rsquo;s an increased risk that the FDA now believes there&rsquo;s something amiss in the roxadustat clinical data that might derail the approval altogether.&rdquo;</p>", "date": "2021-03-05 13:57:00", "meta_title": "FibroGen and AstraZeneca\u00e2\u0080\u0099s roxadustat to face FDA AdCom", "meta_keywords": "FibroGen, AstraZeneca, Roxadustat, FDA, AdCom, Anemia, Kidney disease", "meta_description": "FibroGen and AstraZeneca\u00e2\u0080\u0099s roxadustat to face FDA AdCom", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-03-05 13:54:42", "updated": "2021-03-05 14:06:33", "access": NaN, "url": "https://www.thepharmaletter.com/article/fibrogen-and-astrazeneca-s-roxadustat-to-face-fda-adcom", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "fibrogen_large.png", "image2id": "fibrogen_small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Pharmaceutical", "therapy area_tag": "Nephrology and Hepatology", "topic_tag": "Focus On, Regulation, US FDA", "geography_tag": "UK, USA", "company_tag": "AstraZeneca, FibroGen, ICER", "drug_tag": "roxadustat", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-03-05 13:57:00"}